Drug products: Avopenin, Fenoximetylpenicillin EQL Pharma, Kåvepenin®, Kåvepenin® Frukt, Peceve®, Primve, Tikacillin
ATC code: J01CE02
Controlled studies on differences between men and women regarding the effect, safety and pharmacokinetics of fenoximetylpenicillin are lacking. A smaller study indicates that exposure of fenoximetylpenicillin during pregnancy can be lower than in non-pregnant women, and dose adjustment thus can be needed.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
A pharmacokinetic study described changes in phenoxymethylpenicillin pharmacokinetics during pregnancy (12 pregnant women, 6 non-pregnant controls), in comparison to non-pregnant circumstances. Following a single dose, half-life was shorter during the third trimester compared to the non-pregnant state. Also, exposure was lower for women in the second trimester of pregnancy than for non-pregnant women. These findings indicate increased elimination of phenoxymethylpenicillin during mid and late pregnancy, although differences in elimination were non-significant. The authors recommend reduced dosing-interval or increased dose of phenoxymethylpenicillin in pregnant women .
No studies with a clinically relevant sex analysis regarding the effect of phenoxymethylpenicillin have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of phenoxymethylpenicillin have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
A retrospective study, including 1921 patients (794 men, 1122 women, lack of access to 5 medical records), found a greater occurrence of positive penicillin skin test result in female patients than in male patients with self-reported penicillin allergy. The risk was calculated from the whole set of 64 positive results (11 men, 53 women), including different penicillins .
Date of litterature search: 2014-12-16
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson